SF3B1 and B-cell chronic lymphocytic leukemia: The proportion of RG7388-resistant cases in the SF3B1 mutant group was significantly different from that in the SF3B1 wild-type group (Figure 4D), suggesting that the SF3B1 mutations can modulate protein function in CLL in ways that alter drug response.